NeuroScientific Biopharmaceuticals Ltd - Novel drug therapies for neurodegenerative conditions - Ausbiotech Investment

NeuroScientific
Biopharmaceuticals Ltd
     Novel drug therapies for neurodegenerative
     conditions

DISCLAIMER
The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd
(“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the
information they contain may require further explanation and/or clarification. Further information is available upon
request.

The views expressed in this presentation contain information derived from publicly available sources that have not
been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability
of the information. Any forward looking statements in this presentation have been prepared on the basis of a
number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about
future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific’s
control. Important factors that could cause actual results to differ materially from assumptions or expectations
expressed or implied in this presentation include known and unknown risks. Because actual results could differ
materially to assumptions made and NeuroScientific’s current intentions, plans, expectations and beliefs about the
future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this
presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any
jurisdiction.

3

     CORPORATE OVERVIEW

    ▹ Completed IPO listing on the ASX    Capital Structure

      on the 27 July 2018                 ASX code                    NSB

                                          Shares on issue             73,580,592
    ▹ Lead candidate funded through to
      completion of Phase I               Price (close 29/10/2018)    $0.165

                                          Market cap                  $12.4M
    ▹ Pipeline of potential therapeutic   Shares escrowed 12-months   1,906,269
      candidates with strong IP
      protection                          Shares escrowed 24-months   19,349,506

4

     BOARD & MANAGEMENT

                                                                                          STEPHEN
      BRIAN LEEDMAN             MATT LIDDELOW           DR ANTON UVAROV
                                                                                         QUANTRILL
    Co-founder of ResApp      >12 years experience      Founding director of        20 years’ experience in
    Health Ltd (ASX.RAP),     commercialising medical   Actinogen (ASX:ACW),        corporate advisory and
    Imugene Ltd (ASX:IMU)     devices and               conducting the largest      company directorship,
    and Oncosil Ltd           pharmaceuticals for       Alzheimer’s study in        Executive Chairman of
    (ASX.OSL)                 Australian and multi-     Australasia with 174        McRae Investments.
                              national companies        patients. Former analyst
                              including AstraZeneca.    with Citigroup, New York.

     Non-executive Chairman          MD & CEO               Executive Director       Non-executive Director

5

    COMPANY HIGHLIGHTS

        Advanced preclinical lead drug candidate with multiple
                       treatment indications

        Strong strategic partnerships geared towards success

               Validated strategy and business model

             Experienced board and management team

6

    TREATMENT MARKETS WITH UNMET NEED

    Alzheimer’s disease          Optic nerve conditions
          48M people globally
          have dementia                5% of population
                                       suffer vision loss due to
           70% of dementias            damaged optic nerve
           Alzheimer’s disease
                                       60M people
          US $818B global              affected by glaucoma
          economic burden

7

    LEAD CANDIDATE: EMTINB
                                NOVEL
        Modeled on MT-II protein
        Binds LRP-1 receptors – novel MOA
        Stops cell death & stimulates regeneration

                               VALIDATED
        Preclinical in vitro models – successfully repeated
        Animal models

                        MULTIPLE INDICATIONS
        MOA: LRP-1 receptor ubiquitous
        Not directly targeting a process of disease

8

    EVOLUTION OF EMTINB

        MT-II Structure            EmtinB Peptide             EmtinB Peptide
                                                                Dendrimer

       β-domain       α-domain

    ▹ 61 amino acid length        ▹ 14 amino acid length      ▹ Synthesised as a
    ▹ Binds divalent metal ions   ▹ Isolated from the β-        dendrimer:
    ▹ Difficult to manufacture      domain of MT-II protein     Increased potency and
                                                                  stability

9
    EMTINB MECHANISM OF ACTION:
    Binding LRP-1 receptor

10
        EMTINB SCIENTIFIC DATA
        Preclinical studies
          Increased mean survival of                                    Stimulates neurite
               brain cells >90%                                      outgrowth by up to 300%
          Cell survival: 48-hour incubation period                 Neurite length: 24-hour treatment period

     EmtinB                92%                       EmtinB                        225%
     Induced
                      64%                            Control         100%
     toxicity

     Control                 100%                             0%       50%       100%       150%       200%   250%

                0%            50%              100
                                                %

11
      EMTINB SCIENTIFIC DATA
      Preclinical studies in AD models
     Prevented cell death in in vitro   Slowed progression of disease
      Alzheimer’s model of toxicity     (memory impairment) by >80%
                                         in Alzheimer’s animal model
       Control                100%            Cognition: treatment for 48 days

        Aβ-42         50%                  EmtinB               70%          +7

                                           Control        38%         +5
       EmtinB                 100%

                                                     0%               50%         100
                 0%     50%     100%                                               %

12
     SUPPORTING SCIENTIFIC DATA
     Regenerating the optic nerve

     ▹ Precursor to EmtinB (MT-II) stimulated regenerative growth of optic nerve
       after complete surgical transection

                           Optic Nerve Growth
                                                Treatment

                                                No treatment

13

     EMTINB DEVELOPMENT SCHEDULE

                                                   2018   2018   2019   2019   2019   2019
                                                    Q3     Q4     Q1     Q2     Q3     Q4
        Alzheimer’s disease indication

         Preclinical safety & toxicology studies

           Additional AD animal efficacy study

                          Phase I clinical study

        Ophthalmology indication

                      Preclinical safety studies

                    Preclinical efficacy studies

                       Phase I clinical studies

14

      STRATEGIC PARTNERSHIPS

     ▹ Partner for preclinical studies          ▹ Partner for ophthalmology studies
     ▹ Managed >3300 unique compounds           ▹ Developed 1st artificial cornea
     ▹ >500 IND/CTD programs in the last        ▹ Developed 1st transgenic animal
       5-years                                    model for macular degeneration
     ▹ Offer complete development solution      ▹ Glaucoma treatment recently
       from preclinical to clinical to market     acquired by global pharma Allergan

15
     DEVELOPMENT PIPELINE

                                               Preclinical Phase                    Clinical Phase

                                    Lead           Animal           Safety &    Phase Ia      Phase Ib
                                optimisation       efficacy        toxicology

      Alzheimer’s disease                       EmtinB

      Degenerative
      conditions of the optic       EmtinB
      nerve
      Other Emtin peptides

16

       BUSINESS MODEL
     ▹ Company will seek to out-license EmtinB for late-stage clinical development
     ▹ Potential for multiple treatment indications will be attractive to “big pharma”

17

     KEY MILESTONES

          Nov / DEC-18                                           FEB-19
     Report on ocular tissue                               Results on additional
      distribution study in                                efficacy study in CVN
             rabbits.                                       Alzheimer’s model

                                       JAN-19                                           APR / May-19
                               Results on efficacy study                           Expected conclusion of
                                in glaucoma pig model                              safety & toxicity studies